QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

(2013) Rashmi R. Shah et al.   DRUG SAFETY

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

(2011) J. Tabernero et al.   CLINICAL CANCER RESEARCH

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Richard H. de Boer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

(2011) Yuan Yuan et al.   Journal of Hematology & Oncology

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis

(2009) G. Di Lorenzo et al.   ANNALS OF ONCOLOGY

QT interval prolongation among patients treated with angiogenesis inhibitors

(2009) Stephane Ederhy et al.   Targeted Oncology

Association of antipsychotic and antidepressant drugs with Q-T interval prolongation

(2008) W. R. Zemrak et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

(2008) C. S. Tam et al.   BLOOD

Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels

(2008) De-Yong Zhang et al.   CELLULAR SIGNALLING

450 POSTER NPI-2358, a novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522

(2008) S. Neuteboom et al.   EJC SUPPLEMENTS

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer

(2008) Katsuyuki Kiura et al.   Journal of Thoracic Oncology